secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001682852-22-000049
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna Q3 net income $1.0B, EPS $2.53; lowers 2022 sales view to $18-19B
-------------------------------------------------------------------------

- Q3 revenue $3.4B (down 32% YoY), GAAP net income $1.0B, diluted EPS $2.53 (down 67%).
- Product sales $3.1B, down 35%; cost of sales 35% including $333M write-downs and $209M unutilized capacity.
- 2022 sales guidance lowered to $18-19B ($2-3B deferred to 2023); 2023 preliminary APAs $4.5-5.5B.
- Completed $3B buyback; new $3B program underway; cash $17.0B.
- Pipeline: PCV Phase 2 data Q4 2022; RSV Phase 3 data this winter; flu Phase 3 data Q1 2023; $250M from Merck.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285222000049/0001682852-22-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285222000049/mrna-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001682852-22-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer